3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Breast Neoplasms
350
Polycystic Ovary Syndrome
39
Endometrial Neoplasms
22
Neoplasm Metastasis
21
Ovarian Neoplasms
16
Infertility
12
Neoplasms
11
Fallopian Tube Neoplasms
8
Advanced Breast Cancer
8
Triple Negative Breast Neoplasms
7
Carcinoma, Intraductal, Noninfiltrating
7
Carcinoma, Ductal, Breast
7
Breast Neoplasms, Male
7
Recurrence
6
Osteoporosis
6
Carcinoma, Lobular
6
Breast Diseases
6
Breast Carcinoma In Situ
6
Prostatic Neoplasms
5
Leiomyoma
4
Infertility, Female
4
Hereditary Sensory and Autonomic Neuropathies
4
Breast Cancer Metastatic
4
Neoplasms, Hormone-Dependent
3
Carcinoma, Ovarian Epithelial
3
Carcinoma, Non-Small-Cell Lung
3
Anovulation
3
Uterine Neoplasms
2
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Interventions
Doxorubicin
18
Ifosfamide
13
Radiotherapy
8
Paclitaxel
7
pazopanib
6
pembrolizumab
4
Gemcitabine
4
Filgrastim
4
Chemotherapy, Adjuvant
4
Bevacizumab
4
spartalizumab
3
durvalumab
3
Sorafenib
3
Propranolol
3
Nivolumab
3
Ipilimumab
3
Imatinib Mesylate
3
Etoposide
3
Epirubicin
3
Docetaxel
3
Carboplatin
3
trebananib
2
regorafenib
2
cixutumumab
2
cemiplimab
2
carotuximab
2
brostallicin
2
belinostat
2
balstilimab
2
Vincristine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Hemangiosarcoma
×
Letrozole
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled